Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other solid neoplasm 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Prostatic Neoplasms 657Carcinoma, Renal Cell 385Carcinoma, Non-Small-Cell Lung 243Urinary Bladder Neoplasms 235Breast Neoplasms 221Melanoma 193Ovarian Neoplasms 192Neoplasms 178Colorectal Neoplasms 161Kidney Neoplasms 152Neoplasm Metastasis 131Carcinoma, Transitional Cell 127Pancreatic Neoplasms 124Lung Neoplasms 121Stomach Neoplasms 114Squamous Cell Carcinoma of Head and Neck 107Sarcoma 99Head and Neck Neoplasms 89Uterine Cervical Neoplasms 88Carcinoma, Hepatocellular 80Triple Negative Breast Neoplasms 76Esophageal Neoplasms 76Endometrial Neoplasms 75Colonic Neoplasms 64Wilms Tumor 56Small Cell Lung Carcinoma 55Carcinoma, Ovarian Epithelial 48Neuroblastoma 47Liver Neoplasms 46Testicular Neoplasms 45

Interventions

Taxes 1Immunoglobulin G 1Disulfides 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Cervical Adenocarcinoma × Genitourinary × Clear all
NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡